Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Published:2022-10 Issue:10 Volume:23 Page:1297-1307
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Saad Fred,Thiery-Vuillemin Antoine,Wiechno Pawel,Alekseev Boris,Sala Nuria,Jones Robert,Kocak Ivo,Chiuri Vincenzo Emanuele,Jassem Jacek,Fléchon Aude,Redfern Charles,Kang Jinyu,Burgents Joseph,Gresty Christopher,Degboe Arnold,Clarke Noel W

Funder

Merck Sharp and Dohme

AstraZeneca

Merck & Co Inc

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. New therapies for castration-resistant prostate cancer: efficacy and safety;Beltran;Eur Urol,2011

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

5. Apalutamide treatment and metastasis-free survival in prostate cancer;Smith;N Engl J Med,2018

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA damage-mediated FTO downregulation promotes CRPC progression by inhibiting FOXO3a via an m6A-dependent mechanism;iScience;2024-08

2. Behandlung uroonkologischer Patienten;Die Onkologie;2024-07-08

3. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value;Advances in Therapy;2024-05-20

4. Highlighting recent progress in the treatment of men with advanced prostate cancer;Current Opinion in Oncology;2024-03-13

5. Protocol for Evaluating the Efficacy and Safety of Radiotherapy for Prostate and Oligometastatic Lesions in Patients With Low-Burden Sensitive Oligometastatic Prostate Cancer: An Open, Exploratory Pilot Clinical Trial;Cancer Control;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3